Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serum lipid profile among sporadic and familial forms of Parkinson’s disease

  • Macías García, Daniel
  • Periñán, María Teresa
  • Muñoz-Delgado, Laura
  • Jiménez-Jaraba, María Valle
  • Labrador, Miguel Ángel
  • Jesús Maestre, Silvia
  • Buiza-Rueda, Dolores
  • Méndez-Del Barrio, Carlota
  • Adarmes-Gómez, Astrid
  • Gómez-Garre, Pilar
  • Mir, Pablo
Brain cholesterol metabolism has been described as altered in Parkinson’s disease (PD) patients. Serum lipid levels have been widely studied in PD with controversial results among different populations and age groups. The present study is aimed at determining if the serum lipid profile could be influenced by the genetic background of PD patients. We included 403 PD patients (342 sporadic PD patients, 30 GBA-associated PD patients, and 31 LRRK2-associated PD patients) and 654 healthy controls (HCs). Total cholesterol, HDL, LDL, and triglycerides were measured in peripheral blood. Analysis of covariance adjusting for sex and age (ANCOVA) and post hoc tests were applied to determine the differences within lipid profiles among the groups. Multivariate ANCOVA revealed significant differences among the groups within cholesterol and LDL levels. GBA-associated PD patients had significantly lower levels of total cholesterol and LDL compared to LRRK2-associated PD patients and HCs. The different serum cholesterol levels in GBA-associated PD might be related to diverse pathogenic mechanisms. Our results support the hypothesis of lipid metabolism disruption as one of the main PD pathogenic mechanisms in patients with GBA-associated PD. Further studies would be necessary to explore their clinical implications., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], and the Fundación Alicia Koplowitz. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program [C-0048-2017] (from Andalusian Regional Ministry of Health). Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias de la Junta de Andalucía [B-0007-2019]. Daniel Macías-García was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). María Teresa Periñán was supported by the Spanish Ministry of Education, Culture and Sports [FPU16/05061]. Miguel Ángel Labrador-Espinosa is supported by University of Seville [USE-18817-A]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease

  • Muñoz-Delgado, Laura
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Martín-Rodríguez, Juan Francisco
  • Labrador, Miguel Ángel
  • Jiménez-Jaraba, María Valle
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
[Background] The neutrophil-to-lymphocyte ratio (NLR) in peripheral blood is a well-established inflammatory marker, but its role in Parkinson's disease (PD) remains unclear., [Objectives] To determine whether a different peripheral immune profile and NLR were present in PD patients., [Methods] We conducted a case–control study that included 377 PD patients and 355 healthy controls (HCs). Leukocytes, subpopulations, and the NLR were measured. Multivariate linear regression analyses were applied to determine the differences between groups and the association between NLR and clinical characteristics in PD. A meta-analysis was performed to clarify the association between NLR and PD., [Results] In our case–control study, the NLR was significantly higher in PD patients compared with HCs (2.47 ± 1.1 vs. 1.98 ± 0.91, P < 0.001). No association between NLR and age at onset, disease severity, or disease duration was found. The meta-analysis showed that the NLR was likely to be higher in PD patients., [Conclusions] PD patients had an altered peripheral immune profile and a higher NLR compared with HCs. © 2021 International Parkinson and Movement Disorder Society, This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], and the Fundación Alicia Koplowitz. Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias de la Junta de Andalucía [B-0007-2019]. Daniel Macías-García was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). Juan F. Martín-Rodríguez was supported by the VI-PPIT-US from the University of Seville [USE-18817-A]. Miguel Ángel Labrador-Espinosa was supported by the University of Seville [USE-19094-G]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Teaching Video NeuroImage: Clues in Myoclonus Evaluation

  • Vélez Gómez, Beatriz
  • Jesús Maestre, Silvia
  • Macías García, Daniel
  • Lechón, Beatriz
  • Mir, Pablo
A 53-year-old woman was presented for the evaluation of visual disturbances, generalized and multifocal myoclonus, and progressive ataxia that began at age 30 years (cf. Video 1). Bilateral cherry-red spots in the macula (figure) and a cortical origin in the EEG-EMG coregistration with back-averaging were observed. Reduced neuraminidase activity in fibroblasts and the homozygous mutation c.403G>A in the NEU1 gene confirmed the diagnosis of sialidosis type I., This research was supported by grants from the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, and PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526 and CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, and PE-0186-2019], and the Fundación Alicia Koplowitz. Silvia Jesús has a “Acción B Clínicos-Investigadores” (Action B Clinicians-Researchers) contract [B-0007-2019] funded by the “Consejería de Salud y Familiar,” and Daniel Macías-García has a Río Hortega contract [CM18/00142] funded by the Health Institute Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Using network analysis to explore the validity and influential items of the Parkinson's Disease Questionnaire-39

  • Schönenberg, Aline
  • Santos-García, Diego
  • Mir, Pablo
  • Wu, Jian-Jun
  • Heimrich, Konstantin G.
  • Mühlhammer, Hannah M.
  • Prell, Tino
Quality of life (QoL) in people with Parkinson´s disease (PD) is commonly measured with the PD questionnaire-39 (PDQ-39), but its factor structure and construct validity have been questioned. To develop effective interventions to improve QoL, it is crucial to understand the connection between different PDQ-39 items and to assess the validity of PDQ-39 subscales. With a new approach based on network analysis using the extended Bayesian Information Criterion Graphical Least Absolute Shrinkage and Selection Operator (EBICglasso) followed by factor analysis, we mostly replicated the original PDQ-39 subscales in two samples of PD patients (total N = 977). However, model fit was better when the "ignored" item was categorized into the social support instead of the communication subscale. In both study cohorts, "depressive mood", "feeling isolated", "feeling embarrassed", and "having trouble getting around in public/needing company when going out" were identified as highly connected variables. This network approach can help to illustrate the relationship between different symptoms and direct interventional approaches in a more effective manner., Open Access funding enabled and organized by Projekt DEAL. Funding to K.H. was provided by the German Research Foundation (DFG) as part of the Clinician Scientist-Program OrganAge (413668513). TP, HMM and KH received funding from a Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research) grant (01GY1804). T.P. received funding from a Bundesministerium für Bildung und Forschung (BMBF, Federal Ministry of Education and Research) grant (01GY2301). P.M. received grants from the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI18/01898], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], and the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], J.J.W. received funding from the National Health Commission of the People's Republic of China (Grant No. Pro20211231084249000238), and for Shanghai Municipal Science and Technology Major Projects (Grant No. 2018SHZDZX01, 21S31902200)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline

  • Labrador, Miguel Ángel
  • Silva-Rodríguez, Jesús
  • Reina-Castillo, María Isabel
  • Mir, Pablo
  • Grothe, Michel J.
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., [Background] Degeneration of the cortically-projecting cholinergic basal forebrain (cBF) is a well-established pathologic correlate of cognitive decline in Parkinson's disease (PD). In Alzheimer's disease (AD) the effect of cBF degeneration on cognitive decline was found to be mediated by parallel atrophy of denervated cortical areas., [Objectives] To examine whether the association between cBF degeneration and cognitive decline in PD is mediated by parallel atrophy of cortical areas and whether these associations depend on the presence of comorbid AD pathology., [Methods] We studied 162 de novo PD patients who underwent serial 3 T magnetic resonance imaging scanning (follow-up: 2.33 ± 1.46 years) within the Parkinson's Progression Markers Initiative. cBF volume and regional cortical thickness were automatically calculated using established procedures. Individual slopes of structural brain changes and cognitive decline were estimated using linear-mixed models. Associations between longitudinal cBF degeneration, regional cortical thinning, and cognitive decline were assessed using regression analyses and mediation effects were assessed using nonparametric bootstrap. Complementary analyses assessed the effect of amyloid-β biomarker positivity on these associations., [Results] After controlling for global brain atrophy, longitudinal cBF degeneration was highly correlated with faster cortical thinning (PFDR < 0.05), and thinning in cBF-associated cortical areas mediated the association between cBF degeneration and cognitive decline (rcBF-MoCA = 0.30, P < 0.001). Interestingly, both longitudinal cBF degeneration and its association with cortical thinning were largely independent of amyloid-β status., [Conclusions] cBF degeneration in PD is linked to parallel thinning of cortical target areas, which mediate the effect on cognitive decline. These associations are independent of amyloid-β status, indicating that they reflect proper features of PD pathophysiology., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI19/01576, PI20/00613, PI22/01704), and the Consejería de Salud y Familias de la Junta de Andalucía (PE-0210-2018, PI-0046-2021). M.A.L.-E. is supported by a PhD scholarship (VI-PPIT-US) from the University of Seville (USE-19094-G). J.S.R. is supported by the “Sara Borrell” program (CD21/00067) of the ISCIII-FEDER. M.I.R.-C. is supported by the “PFIS” program (FI21/00160) of the ISCIII-FEDER. M.J.G. is supported by the “Miguel Servet” program (CP19/00031) of the ISCIII-FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Corticospinal adaptations following resistance training and its relationship with strength: A systematic review and multivariate meta-analysis

  • Gómez-Feria, José
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/)., Neural adaptations to resistance training (RT) and their correlation with muscle strength remain partially understood. We conducted a systematic review and multivariate meta-analysis to examine the effects of metronome-paced (MP), self-paced (SP), and isometric (IM) training on M1 and corticospinal pathway activity. Following MP RT, a significant increase in corticospinal excitability was observed, correlating with increased strength. Conversely, no significant relationship was found after SP or IM training. RT also reduced the duration of the cortical silent period, but this change did not predict strength changes and was not specific to any training modality. No significant effects were found for short-interval intracortical inhibition. Our findings suggest that changes in corticospinal excitability may contribute to strength gains after RT. Furthermore, the relationship between these adaptations and strength appears dependent on the type of training performed., This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. JG-F is supported by the Ministerio de Ciencia e Innovación (Grant FPU16/03550). JFM-R is supported by VI-PPIT-US from the University of Seville (USE-18817-A)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease

  • Periñán, María Teresa
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Martín-Rodríguez, Juan Francisco
  • Muñoz-Delgado, Laura
  • Jiménez-Jaraba, María Valle
  • Buiza-Rueda, Dolores
  • Bonilla-Toribio, Marta
  • Adarmes-Gómez, Astrid
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., [Background] Hyperhomocysteinemia is considered an independent risk factor for cognitive impairment., [Objective] To study the correlation between homocysteine levels and cognitive impairment in patients with PD., [Methods] We conducted a case–control study that included 246 patients with PD, of whom 32 were cognitively impaired. The levels of homocysteine, folate, and vitamin B12 were measured in peripheral blood. Multivariate logistic regression analysis was applied to determine differences in homocysteine levels between PD patients with and without cognitive impairment. A meta-analysis was performed to clarify the role of Hcy levels in PD with cognitive decline. Five polymorphisms in genes involved in Hcy metabolism, including MTHFR rs1801133 and rs1801131, COMT rs4680, MTRR rs1801394, and TCN2 rs1801198, were genotyped., [Results] Our case–control study showed that homocysteine levels were associated with cognitive impairment in PD after adjusting for possible confounding factors such as levodopa equivalent daily dose. The results of our meta-analysis further supported the positive association between homocysteine levels and cognition in PD. We found that the MTHFR rs1801133 TT genotype led to higher homocysteine levels in PD patients, whereas the MTHFR rs1801131 CC genotype resulted in higher folate levels. However, the polymorphisms studied were not associated with cognitive impairment in PD., [Conclusions] Increased homocysteine levels were a risk factor for cognitive decline in PD. However, no association was found between polymorphisms in genes involved in homocysteine metabolism and cognitive impairment in PD. Large-scale studies of ethnically diverse populations are required to definitively assess the relationship between MTHFR and cognitive impairment in PD., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], and the Fundación Alicia Koplowitz. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program [C-0048-2017] (from Andalusian Regional Ministry of Health). Silvia Jesús was supported by the "Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias de la Junta de Andalucía [B-0007-2019]. Daniel Macías-García was supported by the “Río Hortega” program [CM18/00142] from the Instituto de Salud Carlos III (ISCIII-FEDER). Juan Francisco Martín-Rodríguez was supported by the VI-PPIT-US from the University of Seville [USE-18817-A]. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease

  • Muñoz-Delgado, Laura
  • Macías García, Daniel
  • Periñán, María Teresa
  • Jesús Maestre, Silvia
  • Adarmes-Gómez, Astrid
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Jiménez-Jaraba, María Valle
  • Benítez Zamora, Belén
  • Díaz-Belloso, Rafael
  • García-Díaz, Sergio
  • Martín Bórnez, Miguel
  • Pineda-Sánchez, Rocío
  • Carrillo, Fátima
  • Gómez-Garre, Pilar
  • Mir, Pablo
© The Author(s) 2023, corrected publication 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., Peripheral inflammatory immune responses are thought to play a major role in the pathogenesis of Parkinson’s disease (PD). The neutrophil-to-lymphocyte ratio (NLR), a biomarker of systemic inflammation, has been reported to be higher in patients with PD than in healthy controls (HCs). The present study was aimed at determining if the peripheral inflammatory immune response could be influenced by the genetic background of patients with PD. We included a discovery cohort with 222 patients with PD (132 sporadic PD, 44 LRRK2-associated PD (with p.G2019S and p.R1441G variants), and 46 GBA-associated PD), as well as 299 HCs. Demographic and clinical data were recorded. Leukocytes and their subpopulations, and the NLR were measured in peripheral blood. Multivariate lineal regression and post-hoc tests were applied to determine the differences among the groups. Subsequently, a replication study using the Parkinson’s Progression Markers Initiative cohort was performed which included 401 patients with PD (281 sPD patients, 66 LRRK2-PD patients, 54 GBA-PD patients) and a group of 174 HCs. Patients with sporadic PD and GBA-associated PD showed a significantly lower lymphocyte count, a non-significantly higher neutrophil count and a significantly higher NLR than HCs. The peripheral inflammatory immune response of patients with LRRK2-associated PD did not differ from HCs. Our study supports the involvement of a peripheral inflammatory immune response in the pathophysiology of sPD and GBA-associated PD. However, this inflammatory response was not found in LRRK2-associated PD, probably reflecting different pathogenic inflammatory mechanisms., The authors thank the donors and the Hospital Universitario Virgen del Rocío-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT17/0015/0041) for the human specimens used in this study. This work was supported by the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, and PI22/01704], the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019], the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00896], and the Fundación Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases – Project ID No 739510. Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017; from the Andalusian Regional Ministry of Health). Silvia Jesús was supported by the “Acción B Clínicos Investigadores” program from the Consejería de Salud y Familias, Junta de Andalucía (B-0007-2019). Daniel Macías-Garcia was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III. Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III. Rafael Díaz Belloso was supported by pre-doctoral contract for training in health research (PFIS) from Instituto de Salud Carlos III. Sergio García Díaz was supported by an University Teacher Training Programme (FPU) from the Spanish Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of ATP10B in Parkinson disease in a cohort from southern Spain

  • Díaz-Belloso, Rafael
  • Muñoz-Delgado, Laura
  • Martín Bórnez, Miguel
  • Ojeda, Elena
  • Periñán, María Teresa
  • García-Díaz, Sergio
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Pineda-Sánchez, Rocío
  • Jesús Maestre, Silvia
  • Macías García, Daniel
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
  • Gómez-Garre, Pilar
The ATP10B gene has been proposed to play an important role in the development of early-onset Parkinson's disease (PD). Nevertheless, various studies have presented controversial conclusions regarding the involvement of this gene in PD. Here, we screened 1162 patients with PD, employing a targeted resequencing approach to investigate the putative relevance of this gene in a large independent cohort of these patients from southern Spain. Variations were classified according to the American College of Medical Genetics and Genomics criteria. Association studies were performed using data of a representative healthy Spanish population from the Medical Genome Project. Frequent variants were excluded. A total of 68 variants (rare or very rare) were detected in our cohort. Among ATP10B variant carriers, 12.9 % were putative compound heterozygous carriers; of these, 25 % were patients with early-onset PD. No evidence of a relation between any rare variants of ATP10B and PD risk was observed. Therefore, our results do not support a role for ATP10B in the onset of PD, or in the risk of developing it., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Daniel Macías-García was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III (ISCIII-FEDER). Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Addressing the sources of inter-subject variability in E-field parameters in anodal tDCS stimulation over motor cortical network

  • Franco-Rosado, Pablo
  • Callejón, M. Amparo
  • Reina-Tosina, Javier
  • Roa, Laura M.
  • Martín-Rodríguez, Juan Francisco
  • Mir, Pablo
Objetive: .Although transcranial direct current stimulation constitutes a non-invasive neuromodulation technique with promising results in a great variety of applications, its clinical implementation is compromised by the high inter-subject variability reported. This study aims to analyze the inter-subject variability in electric fields (E-fields) over regions of the cortical motor network under two electrode montages: the classical C3Fp2 and an alternative P3F3, which confines more the E-field over this region.Approach.Computational models of the head of 98 healthy subjects were developed to simulate the E-field under both montages. E-field parameters such as magnitude, focality and orientation were calculated over three regions of interest (ROI): M1S1, supplementary motor area (SMA) and preSMA. The role of anatomical characteristics as a source of inter-subject variability on E-field parameters and individualized stimulation intensity were addressed using linear mixed-effect models.Main results.P3F3 showed a more confined E-field distribution over M1S1 than C3Fp2; the latter elicited higher E-fields over supplementary motor areas. Both montages showed high inter-subject variability, especially for the normal component over C3Fp2. Skin, bone and CSF ROI volumes showed a negative association with E-field magnitude irrespective of montage. Grey matter volume and montage were the main sources of variability for focality. The curvature of gyri was found to be significantly associated with the variability of normal E-fields.Significance.Computational modeling proves useful in the assessment of E-field variability. Our simulations predict significant differences in E-field magnitude and focality for C3Fp2 and P3F3. However, anatomical characteristics were also found to be significant sources of E-field variability irrespective of electrode montage. The normal E-field component better captured the individual variability and low rate of responder subjects observed in experimental studies., This work was supported by the was supported by the Asociación Universitaria Iberoamericana de Postgrado (AUIP), Spanish Ministry of Science and Innovation (RTC2019-007150-1, PID2021-127034OA-I00), Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704), Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019, PIN-0097-2020), Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896, PY20_00903), OTOVIRT project (PIN-0097-2020) from Andalusian Government co-funded by FEDER and the Fundación Alicia Koplowitz. PMR is member of the European Reference Network for Rare Neurological Diseases (Project ID 739510). Acknowledgements to Sofia Rita Fernandes for her exhaustive review of this work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study Points to Novel Locus for Gilles de la Tourette Syndrome

  • Tsetsos, Fotis
  • Topaloudi, Apostolia
  • Jain, Pritesh
  • Yang, Zhiyu
  • Yu, Dongmei
  • Kolovos, Petros
  • Tumer, Zeynep
  • Rizzo, Renata
  • Hartmann, Andreas
  • Depienne, Christel
  • Worbe, Yulia
  • Müller-Vahl, Kirsten R.
  • Cath, Danielle C.
  • Boomsma, Dorret I.
  • Wolanczyk, Tomasz
  • Zekanowski, Cezary
  • Barta, Csaba
  • Nemoda, Zsofia
  • Tarnok, Zsanett
  • Padmanabhuni, Shanmukha S.
  • Buxbaum, Joseph D.
  • Grice, Dorothy
  • Glennon, Jeffrey
  • Stefansson, Hreinn
  • Hengerer, Bastian
  • Yannaki, Evangelia
  • Stamatoyannopoulos, John A.
  • Benaroya-Milshtein, Noa
  • Cardona, Francesco
  • Hedderly, Tammy
  • Heyman, Isobel
  • Huyser, Chaim
  • Mir, Pablo
  • Morer, Astrid
  • Mueller, Norbert
  • Munchau, Alexander
  • Plessen, Kerstin J.
  • Porcelli, Cesare
  • Roessner, Veit
  • Walitza, Susanne
  • Schrag, Anette
  • Martino, Davide
  • Tischfield, Jay A.
  • Heiman, Gary A.
  • Willsey, A Jeremy
  • Dietrich, Andrea
  • Davis, Lea K.
  • Crowley, James J.
  • Mathews, Carol A.
  • Scharf, Jeremiah M.
  • Georgitsi, Marianthi
  • Hoekstra, Pieter J.
  • Paschou, Peristera
[Background] Tourette syndrome (TS) is a childhood-onset neurodevelopmental disorder of complex genetic architecture and is characterized by multiple motor tics and at least one vocal tic persisting for more than 1 year., [Methods] We performed a genome-wide meta-analysis integrating a novel TS cohort with previously published data, resulting in a sample size of 6133 individuals with TS and 13,565 ancestry-matched control participants., [Results] We identified a genome-wide significant locus on chromosome 5q15. Integration of expression quantitative trait locus, Hi-C (high-throughput chromosome conformation capture), and genome-wide association study data implicated the NR2F1 gene and associated long noncoding RNAs within the 5q15 locus. Heritability partitioning identified statistically significant enrichment in brain tissue histone marks, while polygenic risk scoring of brain volume data identified statistically significant associations with right and left thalamus volumes and right putamen volume., [Conclusions] Our work presents novel insights into the neurobiology of TS, thereby opening up new directions for future studies., This work was supported by EMTICS (FP7-HEALTH, Grant agreement ID No. 278367 [to PP and PJH]), TS-EUROTRAIN (FP7-PEOPLE, Grant agreement ID No. 316978 [to PP]), the National Institute of Neurological Disorders and Stroke (Grant No. R01NS105746), U.S. National Science Foundation (Grant Nos. 2006929 and 1715202 [to PP]), and the National Institute of Mental Health (Grant No. R01MH126213 [to PP]). AJW also received funding from the National Institute of Neurological Disorders and Stroke Grant No. R01NS105746, the Tourette Association of America, and the Weill Institute for Neurosciences. AM received funding from the Deutsche Forschungsgemeinschaft (Grant No. FOR 2698). AS received support from the NIHR UCL/H Biomedical Research Centre. BH is an employee of Boehringer Ingelheim Pharma. CJ received funding from Lundbeck Fonden (Grant No. R100-2011-9332). CB received funding from the Merit-prize fellowship of Semmelweis University, the Bolyai Janos research fellowship of the Hungarian Academy of Sciences (Grant No.BO/00987/16/5), the UNKP-18-4 of the new National Excellence Program of the Ministry of Human Capacities, and the Baron Munchausen Program of the Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University. DCC received funding from the TSAA, the Stichting VC-GGZ, and TS-EUROTRAIN. DM has received research support from Ipsen Corporate and funding grants from Dystonia Medical Research Foundation Canada, Parkinson Canada, The Owerko Foundation, and the Michael P. Smith Family. LKD was supported by grants from the National Institutes of Health (Grant Nos. R01NS102371 and R01NS105746). PM has received grants from the Spanish Ministry of Science and Innovation (Grant No. RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (Grant Nos. PI16/01575, PI19/01576), the Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia (Grant Nos. CVI-02526, CTS-7685), and the Consejeria de Salud y Bienestar Social de la Junta de Andalucia, (Grant No. PE-0210-2018). PJ and CZ were funded by the National Science Center, Poland (Grant No. UMO-2016/23/B/NZ2/03030). ZT was funded by Lundbeck Fonden (Grant No. R100-2011-9332). TIC Genetics (Tourette International Collaborative Genetics) was supported by the National Institutes of Health (Grant Nos. MH115958, MH115960, MH115962, MH115961, MH115993, MH115963, and MH115959) and the New Jersey Center for Tourette Syndrome and Associated Disorder., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis

  • Muñoz-Delgado, Laura
  • Luque-Ambrosiani, Antonio
  • Benítez Zamora, Belén
  • Macías García, Daniel
  • Jesús Maestre, Silvia
  • Adarmes-Gómez, Astrid
  • Ojeda-Lepe, Elena
  • Carrillo, Fátima
  • Mir, Pablo
Background and purpose Peripheral inflammation is probably involved in the pathogenesis of progressive supranuclear palsy (PSP) and it may be a common feature with Parkinson's disease (PD). The peripheral immune profile in PSP remains unclear, as well as whether the inflammatory pathways differ from those in PD. The neutrophil-to-lymphocyte ratio (NLR) has been proven to be a well-established biomarker of systemic inflammation. This study aimed to evaluate the peripheral immune profile in PSP compared with PD. Methods A cross-sectional study was conducted including patients with PSP and PD and healthy controls (HCs). Leukocyte subpopulations and the NLR were measured in peripheral blood. Multivariate linear regression and post hoc tests were applied. Electronic databases were searched in November 2023 to perform meta-analyses to clarify the peripheral immune profile in PSP. Results Our cohort included 121 patients with PSP, 127 patients with PD and 266 HCs. The NLR was higher in PSP and PD compared with HCs. PSP had a higher neutrophil count compared with HCs. Whilst a lower lymphocyte count was found in PD compared with HCs, the lymphocyte count did not differ between PSP and HCs. The meta-analyses supported this immune profile. Conclusions PSP and PD show an increased peripheral inflammation and a higher NLR compared with HCs. Different pathogenic inflammatory mechanisms are probably involved in PSP and PD, since in PSP this altered peripheral immune profile is mainly driven by neutrophils. Understanding the neutrophils' role in PSP may allow for the development of targeted therapies., This work was supported by the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022), the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases—Project ID No. 739510 and L.M.D. and P.M. are members of the COST Action IMMUPARKNET (CA21117). L. Muñoz-Delgado was supported by the ‘Río Hortega’ programme (CM21/00051) from the Instituto de Salud Carlos III, and has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Merz and Italfarmaco. A. Luque-Ambrosiani and B. Benítez-Zamora report no disclosures. D. Macías-Garcia was supported by the ‘Juan Rodés’ programme (JR22/00073) from the Instituto de Salud Carlos III, and has received support for attending meetings and/or travel or honorarium for lecturing from Palex, Abbvie and Italfarmaco. S. Jesús has received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Abbvie, Bial, Italfarmaco, Merz and Zambon. AD Adarmes-Gómez has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Bial, Italfarmaco, Merz, UCB and Zambon. F. Carrillo has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie and Medtronic. E. Ojeda-Lepe was supported by the ‘Río Hortega’ programme (CM23/00288) from the Instituto de Salud Carlos III (ISCIII-FEDER), and has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Bial, Esteve, Merz and Zambon. P. Mir has received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, Abbvie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cortical hypometabolism in Parkinson's disease is linked to cholinergic basal forebrain atrophy

  • Labrador, Miguel Ángel
  • Silva-Rodríguez, Jesús
  • Okkels, Niels
  • Muñoz-Delgado, Laura
  • Horsager, Jacob
  • Castro-Labrador, Sandra
  • Franco-Rosado, Pablo
  • Castellano-Guerrero, Ana María
  • Iglesias Camacho, Elena
  • San Eufrasio, Manuela
  • Macías García, Daniel
  • Jesús, Silvia
  • Adarmes-Gómez, Astrid
  • Ojeda, Elena
  • Carrillo, Fátima
  • Martín-Rodríguez, Juan Francisco
  • Roldán Lora, Florinda
  • García-Solís, David
  • Borghammer, Per
  • Mir, Pablo
  • Grothe, Michel J.
Cortical hypometabolism on FDG-PET is a well-established neuroimaging biomarker of cognitive impairment in Parkinson's disease (PD), but its pathophysiologic origins are incompletely understood. Cholinergic basal forebrain (cBF) degeneration is a prominent pathological feature of PD-related cognitive impairment and may contribute to cortical hypometabolism through cholinergic denervation of cortical projection areas. Here, we investigated in-vivo associations between subregional cBF volumes on 3T-MRI, cortical hypometabolism on [18F]FDG-PET, and cognitive deficits in a cohort of 95 PD participants with varying degrees of cognitive impairment. We further assessed the spatial correspondence of the cortical pattern of cBF-associated hypometabolism with the pattern of cholinergic denervation in PD as assessed by [18F]FEOBV-PET imaging of presynaptic cholinergic terminal density in a second cohort. Lower volume of the cortically-projecting posterior cBF, but not of the anterior cBF, was significantly associated with extensive neocortical hypometabolism [p(FDR) < 0.05], which mediated the association between cBF atrophy and cognitive impairment (mediated proportion: 43%, p < 0.001). In combined models, posterior cBF atrophy explained more variance in cortical hypometabolism (R2 = 0.26, p < 0.001) than local atrophy in the cortical areas themselves (R2 = 0.16, p = 0.01). Topographic correspondence analysis with the [18F]FEOBV-PET pattern revealed that cortical areas showing most pronounced cBF-associated hypometabolism correspond to those showing most severe cholinergic denervation in PD (Spearman's ρ = 0.57, p < 0.001). In conclusion, posterior cBF atrophy in PD is selectively associated with hypometabolism in denervated cortical target areas, which mediates the effect of cBF atrophy on cognitive impairment. These data provide first-time in-vivo evidence that cholinergic degeneration represents a principle pathological correlate of cortical hypometabolism underlying cognitive impairment in PD., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1, PID2021-127034OA-I00), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896, P20_00903), and the Fundación Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (project ID 739510). M.A.L.E. is supported by a PhD scholarship (VI-PPIT-US) from the University of Seville (USE-19094-G). J.S.R. is supported by the “Sara Borrell” program (CD21/00067) of the ISCIII-FEDER. M.J.G. is supported by the “Miguel Servet” program (CP19/00031) of the ISCIII-FEDER. N.O. is supported by the Danish Parkinson’s Disease Association and the Health Research Foundation of Central Denmark Region. L.M.D. is supported by the “Río Hortega” program (CM21/00051) of the ISCIII-FEDER. D.M.G. is supported by the “Juan Rodés” program (JR22/00073) of the ISCIII-FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease

  • Diaz-Galván, Patricia
  • Franco-Rosado, Pablo
  • Silva-Rodríguez, Jesús
  • Castro-Labrador, Sandra
  • Labrador, Miguel Ángel
  • Muñoz-Delgado, Laura
  • Grothe, Michel J.
  • Mir, Pablo
[Data Availability] All clinical data and raw MRI scans used in this study are available in the PPMI database.30 The identity (ID) numbers of the participants included in this study, the MRI data before processing, and R scripts for statistical analyses in this study will be made available on request to facilitate replication of the findings., [Background and Objectives] Accumulating evidence suggests that physical activity is associated with a better clinical and cognitive course in Parkinson disease (PD), yet whether these effects are subserved by structural brain alterations are largely unexplored. The aim of this study was to investigate whether regular physical activity associates with a reduced longitudinal rate of neurodegeneration and slower cognitive decline in PD., [Methods] In this longitudinal, observational cohort study, we used data from the Parkinson's Progression Markers Initiative. We included patients with early PD who had serial assessments of regular physical activity, measured using the Physical Activity Scale for the Elderly, along with serial MRI scans from at least 2 time points over 4 years of follow-up. Regional cortical thickness and subcortical volumes were calculated using established procedures. We used multivariate linear mixed-effects models to analyze the effect of regular physical activity on the progression of MRI parameters over time. We further used mediation models with nonparametric bootstrap to test mediation effects of longitudinal structural brain changes on the association between regular physical activity and longitudinal cognitive functioning., [Results] A total of 120 patients with early PD were included (mean [SD] age = 60.8 [9.3] years; 33% women). Average regular physical activity levels over time were significantly associated with slower cortical thinning in temporoparietal cortical regions, including the lateral temporal cortex, the fusiform gyrus, the parahippocampal gyrus, and the inferior parietal cortex (p < 0.05). Regular physical activity levels over time were also associated with slower volume loss in the hippocampus and the amygdala (p < 0.05). The association of regular physical activity with slower decline in memory and attention functions was mediated by slower decreases in temporoparietal cortical thickness (βPASE-HVLT, = 0.06, p = 0.050; βPASE-SDMT = 0.04, p = 0.017) and hippocampal volume (βPASE-SDMT = 0.03, p = 0.016)., [Discussion] Regular physical activity is associated with a slower rate of neurodegeneration in the temporoparietal cortex and limbic areas in PD, which contributes to preserved cognitive function and improved long-term outcomes. This supports regular physical activity as a key intervention to delay disease progression and improve quality of life in patients with PD., This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), funded by the Instituto de Salud Carlos III and co-funded by the European Union (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512); the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685); the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019); the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022); the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896, PY20_00903); and the Alicia Koplowitz Foundation. MJG is supported by the “Miguel Servet” program of the ISCIII-FEDER (CP19/00031)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

EEG changes induced by dopamine replacement therapy in Parkinson’s disease with impulse control disorders

  • Martín-Rodríguez, Juan Francisco
  • Iglesias Camacho, Elena
  • Gómez-Campos, Francisco Javier
  • Franco-Rosado, Pablo
  • Garrote-Espina, Lorena
  • Muñoz-Delgado, Laura
  • Jesús Maestre, Silvia
  • Macías García, Daniel
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
[Objectives] Impulse control disorders (ICDs) are a common complication in Parkinson’s disease (PD) patients undergoing dopaminergic therapy. Although neurophysiological markers of ICDs have been identified, the effect of dopaminergic therapy on these markers is not fully understood. This study investigates the effect of dopaminergic therapy on EEG oscillatory activity in PD patients with and without ICDs., [Methods] A total of 26 PD patients—14 with ICDs (PD + ICD) and 12 healthy controls (HC)—participated. EEG recordings were obtained during regular dopamine therapy (ON) and after overnight withdrawal (OFF). Spectral analysis assessed group differences in EEG activity and the effect of dopaminergic treatment, while correlations between neurophysiological parameters and impulsivity were analysed., [Results] Results showed increased theta power (4–7.5 Hz) in the fronto-central regions of PD+ICD patients in the OFF state compared to healthy controls. In the ON state, PD+ICD patients showed increased frontal high beta (21–30 Hz) and central alpha (8–12 Hz) activity. Frontal beta activity correlated with impulsivity, independent of treatment dose., [Conclusions] PD + ICD patients show distinct neurophysiological profiles influenced by dopaminergic treatment, highlighting the modulatory effect of therapy on EEG patterns in these patients., [Significance] This study highlights the modulatory effect of dopaminergic therapy on EEG oscillatory patterns in PD patients with ICDs., We are very grateful to the individuals who participated in this study. This work was supported by a Grant PID2021-127034OA-I00 funded by MCIN/AEI/10.13039/501100011033 and, by “ERDF A way of making Europe”, the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI22/01704), the Fundación Progreso y Salud (PI-0055-2014), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformacion Economica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00903), and the Fundacion Alicia Koplowitz. Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (project ID 739510). L.M.D. and P.M.R. are members of the COST Action IMMUPARKNET (CA21117). D.M.G. was supported by the “Juan Rodés” program [JR22/00073] from the Instituto de Salud Carlos III (ISCIII-FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HMGCR genetic variability in Parkinson's disease in a Spanish cohort: associations with lipid metabolism and early onset

  • Díaz-Belloso, Rafael
  • Martín Bórnez, Miguel
  • Macías García, Daniel
  • García-Díaz, Sergio
  • Bonilla-Toribio, Marta
  • Buiza-Rueda, Dolores
  • Pineda-Sánchez, Rocío
  • Muñoz-Delgado, Laura
  • Ojeda, Elena
  • Jesús, Silvia
  • Adarmes-Gómez, Astrid
  • Carrillo, Fátima
  • Mir, Pablo
  • Gómez-Garre, Pilar
Lipid metabolism has emerged as a key factor in the pathophysiology of Parkinson’s disease (PD). While 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate-limiting enzyme in cholesterol biosynthesis, has been implicated in neurodegenerative disorders, such as Alzheimer disease, its role in PD remains unexplored. Given the shared pathological features between these neurodegenerative disorders (such as lysosomal dysfunction and lipid dysregulation) we hypothesized that HMGCR genetic variability could influence PD susceptibility and/or phenotypic expression, particularly in early-onset cases (EOPD). Therefore, we performed targeted sequencing of HMGCR in 1162 Spanish PD patients and analyzed associations with PD risk or age at onset. Replication was attempted in 436 PD cases from Parkinson’s Progression Markers Initiative (PPMI). We identified 21 HMGCR variants, including a likely pathogenic variant affecting the splice site of exon 4 (c.278-1G > A) in a patient with early-onset PD (EOPD), rapid progression, and severe dyslipidemia. The rs5908 variant was significantly associated with EOPD in our cohort (OR = 2.22, p = 0.025). Further analysis revealed rs5908 is in linkage disequilibrium with rs115169875, an intronic variant with putative regulatory impact. Our findings nominate HMGCR as a candidate gene for PD development, particularly in early-onset cases. The metabolic profile of the c.278-1G > A carrier parallels GBA-associated PD, suggesting convergent lipid-lysosomal pathways in neurodegeneration. While cohort differences highlight population-specific genetic effects, these findings underscore the importance of lipid pathways in PD and the need to explore HMGCR’s role in PD subtypes with metabolic comorbidity., Funding for open access publishing: Universidad de Sevilla/CBUA. This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150–1), and funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875, PI24/00632), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471–2013, PE-0210–2018, PI-0459–2018, PE-0186–2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048–2017) from Andalusian Regional Ministry of Health. Rafael Díaz Belloso and Miguel Martín Bornez were supported by pre-doctoral contracts for training in health research (PFIS) from Instituto de Salud Carlos III, with grant numbers FI20/00173 and FI22/00226, respectively. Daniel Macías-García was supported by the “Juan Rodés” program (JR22/00073) from the Instituto de Salud Carlos III (ISCIII- FEDER). Laura Muñoz-Delgado was supported by the “Río Hortega” program (CM21/00051) from the Instituto de Salud Carlos III (ISCIII- FEDER). Sergio García Díaz was supported by a University Teacher Programme (FPU20/00723) from the Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no competing interests to declare that they are relevant to the content of this article., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"

  • Muñoz-Delgado, Laura
  • Williams-Gray, Caroline H.
  • Garraux, Gaetan
  • Clemente, Diego
  • Öztop-Çakmak, Özgür
  • Greenland, Julia C.
  • Figueira, Inês
  • Machín-Díaz, Isabel
  • Pirovano, Elenamaria
  • Di Flora, Alessia
  • Tournerie, Clotilde
  • Papoutsopoulou, Stamatia
  • Ertan, Sibel
  • Mir, Pablo
  • Comi, Cristoforo
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed